After growing steadily for the past few years, China Medical (中国医疗技术公司) is facing a variety of problems: the company had to fight off charges of inaccurate financial reports; it had to lower prices for its ECLIA in vitro diagnostic tests, revenues are flattening for its FISH tests, and the buyer of its HIFU tumor therapy business wants a $15 million rebate (the SFDA has stopped sales of the device until the company completes an additional clinical trial). More details...

Stock Symbol: (NSDQ: CMED)